Moisand Fitzgerald Tamayo Exits Position in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Moisand Fitzgerald Tamayo has sold out all of its stake in Abbott Laboratories during the most recent quarter, according to the disclosure filed by the company on Aug 3, 2016 with the SEC. The investment management company has sold out 27 shares of Abbott Laboratories which is valued at $1,214.

Other Hedge Funds, Including , Diam Ltd. reduced its stake in ABT by selling 1,877 shares or 1.26% in the most recent quarter. The Hedge Fund company now holds 146,961 shares of ABT which is valued at $6,605,897. Abbott Laboratories makes up approx 0.10% of Diam Ltd.’s portfolio. Deltec Asset Management added ABT to its portfolio by purchasing 106,000 company shares during the most recent quarter which is valued at $4,629,020. Abbott Laboratories makes up approx 1.11% of Deltec Asset Management’s portfolio.Bender Robert Associates reduced its stake in ABT by selling 880 shares or 5.95% in the most recent quarter. The Hedge Fund company now holds 13,917 shares of ABT which is valued at $600,797. Abbott Laboratories makes up approx 0.40% of Bender Robert Associates’s portfolio.Telemus Capital boosted its stake in ABT in the latest quarter, The investment management firm added 102 additional shares and now holds a total of 29,689 shares of Abbott Laboratories which is valued at $1,266,236. Abbott Laboratories makes up approx 0.15% of Telemus Capital’s portfolio.Nisa Investment Advisors reduced its stake in ABT by selling 34,004 shares or 6.15% in the most recent quarter. The Hedge Fund company now holds 518,803 shares of ABT which is valued at $21,836,418. Abbott Laboratories makes up approx 0.29% of Nisa Investment Advisors’s portfolio.

Abbott Laboratories closed down -0.24 points or -0.53% at $45.02 with 76,57,947 shares getting traded on Monday. Post opening the session at $45.06, the shares hit an intraday low of $44.88 and an intraday high of $45.41 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Leave a Reply

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.